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Background:  The aim of this study was to determine the clinical effective dose of rocuronium for tracheal intubation 
using a lightwand after induction with propofol, alfentanil, and a low concentration of sevoflurane. 
Methods:  Twenty-eight adults scheduled to undergo elective surgery lasting less than one hour were enrolled in this 
study.  All patients received alfentanil (10 μg/kg) and propofol (1.5 mg/kg) for the induction of anesthesia.  Tracheal 
intubation using a lightwand was attempted 3 minutes after administering rocuronium and mask ventilation with 
2 vol% of sevoflurane.  The initial rocuronium dose was 0.5 mg/kg. The rocuronium dose for consecutive patients, 
determined by Dixon’s up-and-down method, was increased or decreased by 0.05 mg/kg according to the result 
of the previous patient.  The mean arterial pressure and heart rate were recorded before induction, 1 min before 
intubation, 1 and 2 min after intubation.
Results:  The 50% clinical effective dose (cED50) of rocuronium for tracheal intubation using a lightwand was 0.20 ± 0.05 
mg/kg according to Dixon’s up and down method.  Isotonic regression revealed the cED50 and cED95 (95% confidence 
intervals) to be 0.20 mg/kg (0.10-0.3 mg/kg) and 0.35 mg/kg (0.16-0.49 mg/kg), respectively.
Conclusions:  The cED50 and cED95 of rocuronium for tracheal intubation using the lightwand were 0.20 mg/kg and 
0.35 mg/kg, respectively, after induction with alfentanil, propofol, and a low concentration of sevoflurane.  (Korean J 
Anesthesiol 2010; 59: 82-86)
Key Words:  Dixon’s up-and-down method, Lightwand, Rocuronium.
The clinical effective dose of rocuronium for lightwand 
tracheal intubation after induction with alfentanil, propofol, 
and low concentrations of sevoflurane
Hee-Yeon Park, Dongchul Lee, Kyung-Cheon Lee, and Seung-Hwan Kim
Department of Anesthesiology and Pain Medicine, Gil Medical Center, Gachon University of Medicine and Science, Incheon, Korea
Received: January 8, 2010.  Revised: 1st, January 11, 2010; 2nd, March 14, 2010.  Accepted: May 17, 2010.
Corresponding author: Dongchul Lee, M.D., Department of Anesthesiology and Pain Medicine, Gachon University of Medicine and Science Gil 
Medical Center, 1198, Guwol-dong, Namdong-gu, Incheon 405-760, Korea. Tel: 82-32-460-3637, Fax: 82-32-469-6319, E-mail: suasdad@nate.com
    This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
CC83 www.ekja.org
Korean J Anesthesiol Park, et al.
Introduction
    Intravenous or volatile anesthetics and muscle relaxants 
provide adequate intubation conditions in the induction of 
general anesthesia that requires endotracheal intubation. 
Two or three times the 95% clinical effective dose (cED95; 
dose for 95% depression of twitch height) of muscle relaxants, 
which is the usual intubation dose, can achieve adequate 
intubation conditions quickly, but prolongs recovery time of 
neuromuscular function, making it unsuitable for short surgery. 
Rocuronium is a non-depolarizing muscle relaxant with the 
most rapid onset of action and allows intubation within 2 min at 
a lower dose than the usual intubation dose [1,2]. Rocuronium 
is therefore preferred for short procedures or surgery that does 
not require profound neuromuscular blockade.
    Lightwand tracheal intubation is a useful technique for 
patients with limited mouth opening or restricted cervical 
spine movement, as well as for those with unexpected failed 
intubation [3,4]. This technique is relatively simple, with only 
a 1% failure rate and a 92% success rate after the first attempt 
[5]. According to Massó et al. [6], the success rate of tracheal 
intubation using a lightwand was increased by rocuronium 
0.6 mg/kg compared to that without the muscle relaxants. 
However, there is no data on the low rocuronium dose that can 
offer acceptable intubation conditions with lightwand. The 
intubation dose of rocuronium, which has been defined for 
laryngoscopy-guided tracheal intubation, cannot be directly 
translated to the dose for lightwand technique. Therefore, we 
aimed to determine the clinical effective dose of rocuronium for 
lightwand tracheal intubation.
Materials and Methods
    The study was approved by the institutional review board 
and written informed consent was obtained from the subjects. 
American Society of Anesthesiologists physical status I-II adult 
patients who required general anesthesia with orotracheal 
intubation for elective surgery lasting less than one hour 
were examined.  Patients with a history of previous difficult 
intubation or in whom a difficult intubation was suspected 
were excluded. Patients with a known abnormal airway, limited 
cervical spine movement, and body mass index (BMI) > 30 kg/
m
2 were also excluded. 
    Upon arrival at the operating room, the following measure-
ments were assessed for each patient: modified Mallampati 
classification (in the sitting position, tongue maximally forward 
on phonation), mouth opening (MO; the distance between the 
upper and lower incisors with the mouth fully open), and the 
thyromental distance (TMD; the distance from thyroid notch to 
the lower border of the mandibular mentum with the neck fully 
extended). Patients with modified Mallampati classification III 
or IV, MO < 35 mm and TMD < 65 mm were excluded. 
    Midazolam 30 μg/kg was administered intravenously 5 
min before the induction of anesthesia. Standard monitors, 
including an electrocardiogram, noninvasive blood pressure, 
and pulse oximetry were applied. Neuromuscular function was 
assessed by train-of-four (TOF) stimulation of the ulnar nerve, 
using TOF-Watch
Ⓡ (Organon Teknika, The Netherlands) during 
anesthesia induction. Anesthesia was induced with alfentanil 
(10 μg/kg), followed by propofol (1.5 mg/kg) intravenously. After 
confirming mask ventilation, the patients received intravenous 
rocuronium. The rocuronium dose was 0.5 mg/kg for the first 
patient. If lightwand intubation was successful, the rocuronium 
dose was decreased by 0.05 mg/kg in the consecutive patient. 
On the other hand, if it failed, the dose was increased by 
0.05 mg/kg in the consecutive patient. After rocuronium was 
injected, all patients were mask-ventilated mechanically with 
a tidal volume of 10 ml/kg at a respiratory rate of 14 breaths/
min and ventilation was maintained with 2% sevoflurane and 
inspired gas in 100% oxygen 6 L/min for 3 minutes. Tracheal 
intubation using a lightwand (Surch-Lite
TM, Aaron Medical 
Industry, USA) was attempted by one anesthesiologist with 
more than eight years experience in this technique. We used 
7.5-mm-ID and 7.0-mm-ID endotracheal tubes for male and 
female patients, respectively. The distal end of the lightwand 
and covering lubricated tube was bent at a 90
o angle (“hockey 
stick”), and the patient’s head and neck were placed in the 
neutral position. The jaw was lifted forward by an assistant and 
the lightwand and tube were inserted. The ambient light was 
dimmed to allow the visualization of transillumination. The cuff 
of the tracheal tube was inflated immediately after withdrawal 
of the lightwand. The time from inserting the lightwand into the 
oral cavity to visible transillumination at the anterior portion 
of the patient’s neck (defined as the search time) and to the 
confirmation of tracheal intubation with the visualization of 
three expiratory carbon dioxide waveforms during manual 
ventilation (defined as attempt duration) were measured. 
    When the search time exceeded 30 seconds or the endotracheal 
tube had been inserted into the esophagus, a second attempt 
was performed after mask ventilation with 2% sevoflurane and 
inspired gas in 100% oxygen for 1 min. Intubation conditions 
were assessed using a scoring system (0: inability to insert 
tracheal tube into the trachea after two attempts, 1: the presence 
of gross movement of limbs and/or severe cough lasting greater 
than 5 seconds after inserting the tracheal tube into the trachea 
using lightwand, 2: slight movement of limbs and/or some 
diaphragm movement after lightwand tracheal intubation, 3: 
no movement of limbs and diaphragm after lightwand tracheal 
intubation). For score 0, a direct laryngoscopy was performed 
and the laryngoscopic Cormack grade and position of the 84 www.ekja.org
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vocal cord were recorded. A supplemental dose of rocuronium 
(0.2 mg/kg) and propofol (0.5 mg/kg) were then injected and 
tracheal intubation under direct laryngoscopy was attempted 
after mask ventilation for 2 min. Successful lightwand 
intubation was defined as a 2 or 3 score, and failed lightwand 
intubation was defined as a 0 or 1 score. Patients were divided 
into two groups, Group S and group F, according to the results 
of lightwand tracheal intubation. The events including a 
peripheral oxygen saturation <92%, dental trauma, or mucosal 
trauma to the oral cavity or airway were noted. 
    We recorded the train-of-four (TOF) number/ratio that did 
not further decrease more than 3 times consecutively 3 min 
after administering the rocuronium. At this time, end tidal 
sevoflurane concentrations were also noted. The mean arterial 
pressure (MAP) and heart rates (HR) were measured before 
induction, 1 min before intubation, and 1 and 2 min after 
intubation.
    Data is reported as the mean ± SD. Statistical analysis was 
performed using the SPSS version 13.0 for windows (SPSS Inc, 
Chicago, IL, USA). According to Dixon’s up-and-down method 
[7], the study was continued until seven pairs of successful-
failed lightwand intubations had occurred. The 50% clinical 
effective dose (cED50) of rocuronium for lightwand tracheal 
intubation was defined as the mean of the median cross-
over doses. The data was also subjected to isotonic regression 
estimators for calculating the cED95 and the 95% confidence 
interval (CI). An adjusted response probability was easily 
calculated by the pooled adjacent-violators algorithm (PAVA) 
and the CI was estimated by bootstrapping approach [8]. The 
hemodynamic changes during induction in the successful 
intubation group were analyzed by repeated measures ANOVA. 
A P value < 0.05 was considered significant.
Results
    Twenty-eight patients were enrolled in this study when seven 
pairs of successful-failed lightwand intubation had occurred 
(Fig. 1). There were no significant differences in gender, age, 
height, weight, BMI, Mallampati classification, TMD, or MO 
between the successful (Group S) and failed groups (Group F) 
for the lightwand tracheal intubation (Table 1). No Hypoxemia, 
dental trauma, or mucosal trauma during induction occurred in 
either group. The end-tidal sevoflurane concentration (means 
± SD) was 1.04 ± 0.14 vol% after mask-ventilation for 3 min, and 
there was no significant difference between the two groups. The 
TOF number ranged from one to two 3 min after injecting 0.45-
0.50 mg/kg rocuronium. The mean (range) of TOF ratio was 
39% (14-78%) for 0.25-0.4 mg/kg rocuronium and 55% (31-
73%) for 0.1-0.2 mg/kg rocuronium, respectively. The search 
time and attempt duration in Group S were 10.9 ± 4.6 seconds 
and 25.8 ± 4.9 seconds, respectively. For intubation condition 
score 0 (n = 5), endotracheal intubations under a direct 
laryngoscopy were successful and the Cormack grade was I or II 
in all patients (Table 1). However, the vocal cords were closed in 
two patients and mobile in one. Lightwand tracheal intubation 
was successful in the first attempt in all patients except for one 
in Group S. The MAP decreased significantly in group S 1 min 
before intubation compared to that before induction, and the 
HR increased significantly 1 min after intubation compared to 
Table 1. Patients’ Characteristics and Intubation Condition Score
  Group S (n = 17) Group F (n = 11)
Age
Gender (M/F)
Height (cm)
Weight (kg)
BMI (kg/m
2)
Mallampati class (I/II)
TMD (cm)
MO (cm)
Intubation condition score
    0
    1
    2
    3
33.5 ± 14.0
8/9
168.0 ± 10.3
62.8 ± 9.5
22.4 ± 2.0
  7/10
8.0 ± 0.7
4.5 ± 0.5
0
0
8
9
36.4 ± 15.1
5/6
165.8 ± 10.8
61.2 ± 10.9
22.3 ± 3.3
3/8
7.6 ± 0.8
4.4 ± 0.3
5
6
0
0
Values are presented as mean ± SD except for gender, Mallampati 
class, and intubation condition score. There were no significant 
differences between Group S (successful group for lightwand 
tracheal intubation) and Group F (failed group for lightwand 
tracheal intubation). Intubation condition score, 0: inability to insert 
tracheal tube into the trachea after two attempts,1: the presence 
of gross movement of limbs and/or severe cough lasting greater 
than 5 seconds after inserting the tracheal tube into the trachea, 
2: slight movement of limbs and/or some diaphragm movement 
after lightwand tracheal intubation, 3: no movement of limbs and 
diaphragm after lightwand tracheal intubation. BMI: body mass 
index, TMD: thyromental distance, MO: mouth opening.
Fig. 1. Success or failure of intubation using the lightwand on 
the determined rocuronium dose. The mean ± SD of the median 
rocuronium dose of seven success-failure pairs is 0.20 ± 0.05 mg/kg.85 www.ekja.org
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that before induction (Table 2).
    The dose of rocuronium for successful tracheal intubation 
using the lightwand in 50% of patients (cED50) was 0.20 ± 0.05 
mg/kg according to Dixon’s up and down method (Fig. 1). 
Isotonic regression, which was estimated from the PAVA rate, 
revealed an cED50 and cED95 (95% CI) of rocuronium 0.20 mg/
kg (0.09-0.30 mg/kg) and 0.35 mg/kg (0.16-0.49 mg/kg), 
respectively (Fig. 2).
Discussion
    The cED50 and cED95 of rocuronium for tracheal intubation 
using lightwand were 0.20 mg/kg and 0.35 mg/kg, respectively, 
after induction with propofol and alfentanil, and a low 
concentration of sevoflurane in patients with a normal airway 
anatomy.
    Patients in whom a difficult intubation was suspected were 
excluded. In addition, patients with factors that could interfere 
with the ease and success of intubation using lightwand, 
including Mallampati class III and a BMI ≥ 30 kg/m
2 were also 
excluded [9]. The Cormack grade under a direct laryngoscopy 
in the five patients from Group F who could not be intubated 
using a lightwand was I or II, meaning that these patients did 
not have abnormal airway anatomy leading to difficult tracheal 
intubation. Another 6 patients in Group F showed severe cough 
and/or vigorous movement of the limbs after lightwand tracheal 
intubation. From the fact that lightwand intubation failed or 
was successful in the same dose, it was inferred that individual 
sensitivity to muscle relaxant would be reflected.   
    This study calculated the clinically effective dose of rocuronium 
required for lightwand tracheal intubation using Dixon’s up and 
down method and isotonic regression. The rocuronium dose 
that provided clinically acceptable intubation conditions in 95% 
of patients when performing intubation using a lightwand was 
0.35 mg/kg, which is comparable to a low dose for intubation 
under direct laryngoscopy. Rocuronium (0.1 mg/kg) after 
induction with propofol (2.5 mg/kg) and alfentanil (10 μg/
kg) improved intubation conditions significantly compared to 
those without muscle relaxants, and rocuronium (0.3 mg/kg) 
provided acceptable intubation conditions in 90% of patients 
[10]. After induction with remifentanil 2 μg/kg and propofol 
2 mg/kg, rocuronium 0.3 mg/kg provided excellent and good 
intubation conditions in 90% and 9% of patients, respectively 
[11]. Schlaich et al. [12] reported that the intubation conditions 
were poor in 40% of patients without muscle relaxants after 
induction with propofol (2-2.5 mg/kg) and remifentanil (0.5 
μg/kg/min) for 3 min. However, the addition of rocuronium 
(0.45 mg/kg or 0.3 mg/kg) to this regimen improved the 
intubation conditions significantly. In addition, reducing the 
intubation dose of rocuronium shortened its time course of 
action considerably. 
    Several factors contribute to tracheal intubation conditions. 
Satisfactory tracheal intubation can be achieved under deep 
anesthesia alone. However, increasing the dose of hypnotics 
and opioids may have adverse effects, such as hypotension or 
bradycardia, and there is still no guarantee that the optimal 
intubation conditions will be achieved in all patients without a 
muscle relaxant [1]. In addition, tracheal intubation without a 
muscle relaxant may increase the risk of airway trauma [13]. The 
administration of larger multiples of a relaxant’s ED95 provides 
increased reliability and accelerates the onset for tracheal 
intubation but may prolong its duration of action, which is 
unsuitable for short surgery or outpatient surgery. However, 
rocuronium with a rapid onset profile can provide clinically 
acceptable intubation conditions at less than twice the ED95, 
the usual intubation dose [1]. Here, a clinically effective dose 
of rocuronium for lightwand tracheal intubation was obtained 
with usual doses of hypnotics and opioids that provided stable 
Table 2. Hemodynamic Changes during Anesthesia Induction in the Successful Intubation Using the Lightwand 
Before induction 1 min before intubation 1 min after intubation 2 min after intubation
MAP (mmHg)
HR (beats/min)
92.5 ± 12.9
71.4 ± 12.0
68.7 ± 9.3*
64.6 ± 14.2
92.6 ± 14.4
  82.2 ± 16.5*
86.9 ± 14.7
80.1 ± 17.1
Values are presented as the mean ± SD. MAP: mean arterial pressure, HR: heart rate. *P < 0.05 compared to before induction.
Fig. 2. Pooled-adjacent-violators algorithm (PAVA) response rate. 
The 50% and 95% clinical effective dose (95% confidence interval) 
estimated from the PAVA response rate of rocuronium for intubation 
using the lightwand, were 0.20 mg/kg (0.09-0.30 mg/kg) and 0.35 
mg/kg (0.16-0.49 mg/kg), respectively.86 www.ekja.org
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hemodynamic changes (Table 2). 
    The onset time of the neuromuscular blocking agent is asso-
ciated with the dose administered [14]. In Koreans, the onset 
time is 191 s and 159 s with rocuronium 0.1 mg/kg and 0.3 
mg/kg, respectively [15]. The interval between drug admini-
stration and laryngoscopy will be prolonged if tracheal 
intubation is performed with a small dose of nondepolarizing 
neuromuscular agent. Therefore, lightwand tracheal intubation 
was attempted when the TOF ratio had not further decreased 
more than 3 times consecutively 3 min after the administration 
of rocuronium. 
    This study has some limitations. First, objective data showing 
anesthetic depth are lacking. Although all patients received 
the same dose of hypnotics and opioids, they may have 
different degrees of anesthetic depth. Second, neuromuscular 
monitoring was not performed during the operation except 
during the induction period. Consequently, there is no 
information on the actual neuromuscular recovery time at 
these low doses. After injecting rocuronium (0.25 mg/kg), the 
time to spontaneous 90% recovery of the T1 twitch height at the 
adductor pollicis muscle was approximately 10 min [16]. These 
results indicate that the clinical effective dose of rocuronium for 
lightwand tracheal intubation calculated in the present study is 
suitable for short surgery or outpatient surgery. 
    In conclusion, the cED50 and cED95 of rocuronium for 
lightwand tracheal intubation under 2 vol% inspired sevoflurane 
after induction with propofol (2 mg/kg) and alfentanil (10 μg/
kg) were 0.20 mg/kg and 0.35 mg/kg, respectively. These are 
the clinically optimal doses of rocuronium when the lightwand 
technique is needed for short surgical procedures or outpatient 
surgery.
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